This company is engaged in the discovery, development, manufacture, and marketing of pharmaceutical products and services. The company was created in 1989 through a merger between two Danish companies--Novo Industri A/S and Nordisk Gentofte A/S, and has its registered main office in Bagsvaerd, Denmark. The Company operates in two segments: Diabetes Care and Biopharmaceuticals. The Diabetes Care segment provides insulin analogues, human insulin and insulin-related products, and oral antidiabetic drugs. While the Biopharmaceuticals segment offers hemostasis management, growth hormone therapy, and hormone replacement therapy. Specifically, the company's products include Lente, a long-acting insulin zinc suspension; Alcalase, its first detergent enzyme produced by fermentation; Trisequens, sequential combined oral hormone replacement therapy (HRT) for peri-menopausal women; NovoPen, an injection system similar in appearance to a fountain pen, with replaceable insulin cartridges; NovoSeven, for the treatment of haemophilia patients with inhibitor reaction; and Innovo, the world's first insulin doser with a built-in electronic memory. The company is a world leader in diabetes care and has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. The company is dedicated to develop its business towards ecological, social and economic sustainability. The company has production facilities in six countries, with affiliates or offices in 68 countries. The company markets its pharmaceutical products and services to patients, and the medical profession and society. The company distributes its products through its subsidiaries, distributors, and independent agents, primarily in the United States, Japan, and European countries.
La versione in sola lettura del questionario inviato a questa azienda è disponibile pubblicamente: vedi questionario.